Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
about
New Strategies for the Treatment of Solid Tumors with CAR-T CellsChimeric Antigen Receptors Modified T-Cells for Cancer TherapyTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Engineered T cells for cancer treatmentLentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.Construction and evaluation of a novel humanized HER2-specific chimeric receptorSuccessful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.Immunotherapeutic Intervention against Sarcomas.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceTargeted immunotherapy of cancer with CAR T cells: achievements and challenges.Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Genetic modification of T cellsThe promise and potential pitfalls of chimeric antigen receptors.Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vectorImmunotherapy for hepatocellular carcinoma: From basic research to clinical use.Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptorEngineering lymphocyte subsets: tools, trials and tribulationsA fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.Update on vaccine development for renal cell cancer.Adoptive cellular immunotherapy for childhood malignancies.Toxicities of chimeric antigen receptor T cells: recognition and management.Immunotherapy targeting EBV-expressing lymphoproliferative diseasesChimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelTreatment of lymphoma with adoptively transferred T cells.Genetic redirection of T cells for cancer therapy.Enhanced T cell receptor gene therapy for cancer.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Cancer immunotherapy--revisited.Is adoptive T-cell therapy for solid tumors coming of age?Adoptive immunotherapy against sarcomas.Adoptive T-cell therapy: a need for standard immune monitoring.CAR T-Cell Therapy: Progress and Prospects.Harnessing the immune response to target tumors.Engineering CAR-T cells.Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer.
P2860
Q26748500-9B6086CA-4DEA-4F01-A44D-2E7D1110294CQ26773309-D1A9687A-EA72-4D24-B71C-05EB710C582CQ29616128-B882689B-D63C-4834-B436-97BDB8269E52Q33578792-2E0DA833-ECF7-4CB2-9E9E-0BBC66F8320DQ33688441-AA93FDD5-777B-4AEB-96E1-27F99EA3DBE7Q33892746-37021C2A-B75D-4CB8-8D3F-79150CE524EAQ34007762-382B53A4-6E13-43E7-9460-008B2EF7C861Q34042430-C488C2F9-7F47-4548-9704-7BED160C1E51Q34196481-DB4DC8CD-30A9-49FC-B43F-4E0E02FE5654Q34245416-01CF9D0C-A4D9-44B1-AA39-B6941283F841Q34270375-5B051747-E4B2-443F-AC6F-17013305F988Q34310912-0FB3516C-7C6A-4249-AA16-851D1F37A935Q34360292-884EAF08-8F0D-4E1F-B01D-314EDA252C1EQ34592273-D509F8D7-BDED-4B16-9F31-9AE7BD2F7BA2Q34644876-6A496915-3608-4CFA-81AC-1606B1D8ECA5Q34970378-3B8402D7-2B58-47BA-8F7C-9589D48A979AQ35238310-F3CC5E50-F356-484D-B16C-ECFB7B9A1B2EQ35567765-56049B8B-70B2-4319-8B4D-DE024DF95542Q35802193-BAB82AEB-B597-4C69-993B-FB75CF53AF82Q36140986-BA80305D-5C66-4077-B6C7-1C98567EC8BBQ36356392-E01661BE-9E9D-4C33-8BA1-630E3DCA2F14Q36453570-716058CD-120E-4482-964E-F08345AAAA69Q36713904-6DCB0985-0A0B-45F0-BAA5-155B819ED55AQ36989720-B791C450-B934-41AB-BA3B-7007FFFD7967Q37008216-8A28F691-4B67-4ADA-8CEE-60FDE3E1B826Q37058104-C6DF7B28-6570-458E-8CC4-3FCF5000663CQ37268305-B60EE0B6-697F-48E5-9B7D-D04E6AE740EDQ37376269-58065DE4-0452-4C28-8633-D3306ECAC6CDQ37419728-71AF8AA4-F04D-4283-86FD-B4795F0A1B45Q37697337-5E6FE4DA-0CD6-40EC-98AA-A66B20D72385Q37702226-B97F4DAE-5ADA-4730-8301-A9A773CFBFC0Q37751873-D1CE0FAB-D7D3-4450-A28B-92EEEC2642A7Q37908998-7F93A891-18F1-4778-BE59-4DB99C131175Q37909004-CB6D2B46-AA84-4044-B9DD-FF520BF1818BQ38291193-1BE11E24-E4D1-4204-BE0A-312E36EC1317Q38525029-3BE3A27B-154A-4637-87A6-5C552DE9FE7AQ38741433-8FD97B37-E90E-4B67-9A62-F2AD796320DEQ39377265-7A2AF6F6-6145-418E-A4BD-CB2AE6126215Q39399864-8EC3DA09-132A-4EA3-908C-22A31DC0E9CDQ39617589-0E4667A3-9422-4956-864C-E79C2CB4C3D8
P2860
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Gene-modified T cells for adop ...... ific immune functions in vivo.
@ast
Gene-modified T cells for adop ...... ific immune functions in vivo.
@en
Gene-modified T cells for adop ...... ific immune functions in vivo.
@nl
type
label
Gene-modified T cells for adop ...... ific immune functions in vivo.
@ast
Gene-modified T cells for adop ...... ific immune functions in vivo.
@en
Gene-modified T cells for adop ...... ific immune functions in vivo.
@nl
prefLabel
Gene-modified T cells for adop ...... ific immune functions in vivo.
@ast
Gene-modified T cells for adop ...... ific immune functions in vivo.
@en
Gene-modified T cells for adop ...... ific immune functions in vivo.
@nl
P2093
P1476
Gene-modified T cells for adop ...... ific immune functions in vivo.
@en
P2093
Cor H J Lamers
Corrien M Groot-van Ruijven
Jan Willem Gratama
Reno Debets
Sabine C L Langeveld
Stefan Sleijfer
P2888
P304
P356
10.1007/S00262-007-0330-3
P577
2007-05-04T00:00:00Z
P5875
P6179
1018828045